Partendo da MTHFR per arrivare all’omocisteina

• Baszczuk A, Kopczy ski Z. Hyperomocysteinemia in patients with cardiovascular disease. Postepy Hig Med Dosw (Online) 2014;68: 579-89. • Dell’Edera D, Tinelli A, Milazzo GN, et al. Effect of multivitamins on plasma homocysteine in patients with the 5,10 methylenetetrahydrofolate reductase C677T homozygous state. Mol Med Rep 2013; 8(2):609-12. • Joachim E, Goldenberg NA, Bernard TJ, Armstrong-Wells J, Stabler S, Manco-Johnson MJ. The methylenetetrahydrofolate reductase polymorphism (MTHFR c.677C>T) and elevated plasma homocysteine levels in a U.S. pediatric population with incident thromboembolism. Thromb Res 2013;132(2):170-4. • Liew SC, Gupta ED. Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: epidemiology, metabolism and the associated diseases. Eur J Med Genet 2015;58(1):1-10. • Lippi G, Plebani M. Hyperhomocysteinemia in health and disease: where we are now, and where do we go from here ? Clin Chem Lab Med 2012;50(12):2075-80. • Papandreou D, Malindretos P, Arvanitidou M, Makedou A, Rousso I. Oral supplementation of folic acid for two months reduces total serum homocysteine levels in hyperhomocysteinemic Greek children. Hippokratia 2010;14(2):105-8. • Sirachainan N, Tapanapruksakul P, Visudtibhan A, et al. Homocysteine, MTHFR C677T, vitamin B12, and folate levels in Thai children with ischemic stroke: a case-control study. J Pediatr Hematol Oncol 2006;28(12):803-8. • Smulders YM, den Heijer M, Blom HJ. Homocysteine levels: measure or not? Ned Tijdschr Geneeskd 2013;157(44):A6265.